<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115618</url>
  </required_header>
  <id_info>
    <org_study_id>2017-ESCCSIB</org_study_id>
    <nct_id>NCT04115618</nct_id>
  </id_info>
  <brief_title>SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic Esophageal Squamous Cell Carcinoma: a Phase II Study of Single Institution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost
      Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell
      Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity Effect</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Toxicity effect defined as over CTCAE 4 grade 3 acute radiation toxicity of esophagitis 2 weeks after completion of 6 weeks of radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>One month</time_frame>
    <description>Time of disease progression or unrecorded time of death due to any cause from the day of admission to the first imaging confirmation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>One month</time_frame>
    <description>Time from admission to death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous integrated boost intensity-modulated chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Simultaneous integrated boost intensity-modulated chemoradiotherapy</intervention_name>
    <description>Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.</description>
    <arm_group_label>SIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytologic diagnosis of esophageal squamous carcinoma;

          2. Aged 18-75 years;

          3. KPS ≥ 70;

          4. Upper thoracic esophageal squamous carcinoma: the upper margin of the lesion is
             located between the entrance of esophagus and the inferior edge of the azygos vein;

          5. Stage I-IVA(AJCC 6th,2009);

          6. Not able to be surgically resection or rejected;

          7. Not have received any prior anticancer therapy;

          8. No serious system dysfunction and immuno-deficiency, Adequate organ function including
             the following: Hemoglobin ≥9 g/dL, WBC≥4x109/L, Neutrophils (ANC )≥1.5x10^9/L,
             platelet count ≥100x 10^9/L, serum creatinine&lt;1.5 mg/dL,urea nitrogen &lt;8 mmol/L;

          9. No history of malignancy;

         10. No perforation of esophagus, no deep ulcer of esophagus;

         11. Joined the study voluntarily and signed informed consent form.

        Exclusion Criteria:

          1. Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives;

          2. Patient who has metastasis such as lung, liver metastasis;

          3. Other malignant tumors;

          4. Uncontrolled seizures or psychiatric diseases, loss of control over their own
             behavior;

          5. Uncontrollable heart disease, diabetes and hypertension, pulmonary fibrosis, and chest
             confirmed active pulmonary inflammation require antibiotic treatment, as well as
             superior vena cava compression syndrome;

          6. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting
             therapy;

          7. Combination of pure red cell anemia or gamma globulin;

          8. Allergic to any medication component studied.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xi Yang, Phd</last_name>
    <phone>86-17321296901</phone>
    <email>ntgeorge@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Yang, Phd</last_name>
      <phone>86-17321296901</phone>
      <email>ntgeorge@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhengfei Zhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Simultaneous Integrated Boost Intensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

